IMNM - Company ID 0001472012
The table below shows Immunome Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $4.01M | $2.93M | $2.91M | $2.36M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $46.38M | $49.19M | $40.45M | $36.87M | $37.20M | $29.08M |
Immunome Inc. reported annual revenue of $6.94M for fiscal year 2025. That is down 23.2% from $9.04M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $12.95M |
| $10.95M |
| $10.04M |
| $10.69M |
| $9.53M |
| $6.98M |
| Operating income | -$59.33M | -$60.14M | -$46.48M | -$44.64M | -$50.52M | -$40.01M |
| Income tax | - | - | - | - | - | - |
| Net income | -$53.84M | -$57.46M | -$43.40M | -$41.64M | -$47.10M | -$36.12M |
| EPS (diluted) | -$0.48 | -$0.65 | -$0.50 | -$0.52 | -$0.78 | -$0.60 |